Management of egfr tki—Induced Dermatologic Adverse Events

Author:

Melosky B.,Leighl N.B.,Rothenstein J.,Sangha R.,Stewart D.,Papp K.

Abstract

Targeting the epidermal growth factor receptor (EGFR) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy, EGFR tyrosine kinase inhibitors (TKIS) have been associated with improved efficacy in patients with an EGFR mutation. Together with the increase in efficacy comes an adverse event (AE) profile different from that of chemotherapy. That profile includes three of the most commonly occurring dermatologic AES: acneiform rash, stomatitis, and paronychia. Currently, no randomized clinical trials have evaluated the treatments for the dermatologic AES that patients experience when taking EGFR TKIS. Based on the expert opinion of the authors, some basic strategies have been developed to manage those key dermatologic AES. Those strategies have the potential to improve patient quality of life and compliance and to prevent inappropriate dose reductions.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3